Across TCGA pan-cancer cohorts, FLT3LG Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated FLT3LG data layer compared with 24 for mass-spec protein and 7 for mass-spec protein.
The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher FLT3LG Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated FLT3LG expression acts as an unfavorable survival marker.
UCEC and ESCA are the cancer types where FLT3LG Mutation most reproducibly stratifies survival.